Best Places to Work
Filter News
Found 11,589 articles
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/19/2024
CSL Vifor announced that Health Canada has authorized Ferinject for the intravenous treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.
-
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
3/19/2024
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates.
-
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
3/19/2024
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca.
-
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
3/18/2024
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease, including those who are uninsured and underinsured.
-
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
3/18/2024
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio.
-
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
3/18/2024
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform.
-
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
3/15/2024
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy.
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
3/15/2024
Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy met its primary endpoint of overall survival for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.
-
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
3/14/2024
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi®.
-
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
3/14/2024
Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million.
-
Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca
3/14/2024
Sofinnova Partners announced that its portfolio company, Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in the development of therapeutic peptides for rare endocrine and related diseases has entered into a definitive agreement with AstraZeneca for its acquisition, with an upfront purchase price of $800 million and a potential milestone payment of $250 million.
-
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
3/13/2024
PepGen Inc. announced that the U.S. Food and Drug Administration granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy patients whose mutations are amenable to an exon 51 skipping approach.
-
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
3/13/2024
Alnylam Pharmaceuticals, Inc. announced the launch of the Family Health History Road Trip, its program designed to encourage conversations between family members about their health history so they can discuss with their doctor to better understand their risk for developing an inherited disease like hereditary ATTR amyloidosis.
-
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
3/13/2024
AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE®.
-
Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
3/13/2024
IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM.
-
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
3/13/2024
Takeda today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).
-
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
3/13/2024
Pfizer Inc. announced that the European Commission has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
-
PepGen to Participate in Upcoming Investor Conferences - March 13, 2024
3/13/2024
PepGen Inc. announced that management will participate in the following upcoming investor conferences.
-
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
3/13/2024
Merck, known as MSD outside of the United States and Canada, , at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types.
-
Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics
3/12/2024
Pearl Bio today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.